---
title: 'Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL:
  results from the EPCORE NHL-2 trial'
date: '2025-01-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39792928/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20250111170758&v=2.18.0.post9+e462414
source: Blood
description: Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma
  (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a
  standard salvage therapy, yields complete response (CR) rates of approximately 30%
  and median overall survival (OS) of 10-13 months. Patients with refractory disease
  fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months.
  Epcoritamab, a CD3xCD20 bispecific antibody approved for the treatment of R/R DLBCL
  after ...
disable_comments: true
---
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) with rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) of 10-13 months. Patients with refractory disease fare worse, with a CR rate of 7% for subsequent therapies and median OS of 6 months. Epcoritamab, a CD3xCD20 bispecific antibody approved for the treatment of R/R DLBCL after ...